Gubra raised earnings guidance for full-year 2023. Organic revenue growth to be 25-28% compared to previous guidance of 16-21%. EBIT-margin excl.
special items to be 26-28% compared to previous guidance of Around 25%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
328 DKK | -0.30% | +5.47% | +162.40% |
May. 07 | Gubra A/S Announces Management Changes | CI |
Apr. 17 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
Gubra raised earnings guidance for full-year 2023. Organic revenue growth to be 25-28% compared to previous guidance of 16-21%. EBIT-margin excl.
special items to be 26-28% compared to previous guidance of Around 25%.
1st Jan change | Capi. | |
---|---|---|
+162.40% | 777M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |